Huadong Medicine Co.,Ltd.(000963),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

000963 Huadong Medicine Co.,Ltd.

Closed 09-30 15:00:00

34.99

+2.58

+7.96%

High35.17	Low32.91	Vol33.59M
Open33.40	D1 Closing32.41	Amplitude6.97%
Mkt Cap61.37B	Tradable Cap61.27B	Total Shares1.75B
T/O1.15B	T/O Rate1.92%	Tradable Shares1.75B
P/B2.61	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"000963","market":"SZ","secType":"STK","nameCN":"Huadong Medicine Co.,Ltd.","latestPrice":34.99,"timestamp":1727679816000,"preClose":32.41,"halted":0,"volume":33594339,"delay":0,"changeRate":0.0796,"floatShares":1751000000,"shares":1754000000,"eps":1.7678,"marketStatus":"Closed","change":2.58,"latestTime":"09-30 15:00:00","open":33.4,"high":35.17,"low":32.91,"amount":1149000000,"amplitude":0.0697,"askPrice":34.99,"askSize":533,"bidPrice":34.98,"bidSize":32,"shortable":0,"etf":0,"ttmEps":1.7678,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1728351000000},"marketStatusCode":5,"adr":0,"adjPreClose":32.41,"symbolType":"stock","openAndCloseTimeList":[[1727659800000,1727667000000],[1727672400000,1727679600000]],"highLimit":35.65,"lowLimit":29.17,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1754262548,"isCdr":false,"pbRate":2.61,"roa":"--","peRate":19.792963,"roe":"7.8%","epsLYR":1.6219,"committee":-0.39369,"marketValue":61382000000,"turnoverRate":0.0192,"status":0,"nextConnectDate":"Northbound have stopped. The next trading day is UTC+8 2024-10-08.","floatMarketCap":61264000000},"requestUrl":"/m/hq/s/000963","defaultTab":"news","newsList":[{"id":"2471481878","title":"Huadong Medicine Gets Clinical Trial Approvals for Two Skin Cream Variants","url":"https://stock-news.laohu8.com/highlight/detail?id=2471481878","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471481878?lang=en_us&edition=fundamental","pubTime":"2024-09-30 16:35","pubTimestamp":1727685350,"startTime":"0","endTime":"0","summary":"Huadong Medicine  subsidiary Hangzhou Sino-US Huadong Pharmaceutical obtained clinical trial approvals for two variants of its Roflumilast cream, according to a Monday filing with the Shenzhen Stock Exchange.The 0.15% Roflumilast cream is indicated for mild to moderate atopic dermatitis in patients 6 years and older.The 0.3% variant is indicated for patients with plaque psoriasis in patients 6 years and older, including intertriginous areas, where two body parts rub against each other, the filing said.Shares closed 8% higher during Monday's trading.Price : 34.99, Change: +2.6, Percent Change: +7.96%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2328871848.SGD","LU1969619763.USD","000963","BK0183","BK0188","BK0175","BK0187","BK0132","BK0209","BK0196"],"gpt_icon":0},{"id":"2470289862","title":"Huadong Medicine Gets China Device Approval for Radio Frequency Skin Treatment Device","url":"https://stock-news.laohu8.com/highlight/detail?id=2470289862","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470289862?lang=en_us&edition=fundamental","pubTime":"2024-09-25 15:23","pubTimestamp":1727249024,"startTime":"0","endTime":"0","summary":"Chinese authorities granted Huadong Medicine  medical device approval for its V20 intense pulsed light radiofrequency therapeutic device, according to a Wednesday filing with the Shenzhen Stock Exchange.The device uses radio waves to improve skin wrinkles, and remove excess hair, vascular and pigmented lesions, and acne, the filing said.Shares closed 3% higher in Shenzhen during Wednesday's trading.Price : 29.66, Change: +0.86, Percent Change: +2.99%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2328871848.SGD","BK0196","000963","BK0175","BK0188","BK0209","BK0187","BK0183","LU1969619763.USD","BK0132"],"gpt_icon":0},{"id":"2459725751","title":"Huadong Medicine Ends Research on Weight Loss Drug; Shares Jump 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459725751","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459725751?lang=en_us&edition=fundamental","pubTime":"2024-08-16 13:55","pubTimestamp":1723787700,"startTime":"0","endTime":"0","summary":"Huadong Medicine , through unit Hangzhou Sino-US Huadong Pharmaceutical, agreed with US biopharmaceutical firm vTv Therapeutics to end the research and development of weight loss drug TTP273, according to a Friday disclosure on the Shenzhen Stock Exchange.The Chinese pharmaceutical company decided to focus its resources on the research and development of its self-developed drug, HDM1002, after data showed that it was more effective than TTP273 regarding weight loss.TTP273 was in phase II clinical trials when it was called off.The Chinese pharmaceutical company obtained the exclusive license for TTP273 in December 2017.Huadong Medicine's shares jumped more than 5% in recent trade.Price : 28.33, Change: +0.56, Percent Change: +2.02%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0187","BK0188","BK0132","LU1969619763.USD","BK0209","000963","BK0175","BK0196","BK0183","LU2328871848.SGD"],"gpt_icon":0},{"id":"2459257690","title":"Huadong Medicine Ends Research on Weight Loss Drug; Shares Jump 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459257690","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459257690?lang=en_us&edition=fundamental","pubTime":"2024-08-16 13:55","pubTimestamp":1723787700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK0183","VTVT","BK4139","BK0188","LU2328871848.SGD","BK0209","BK0175","BK0132","BK0187","BK0196","SHE","000963","LU1969619763.USD"],"gpt_icon":0},{"id":"2459252798","title":"Huadong Medicine Secures License For IMBiologics' Autoimmune Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2459252798","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459252798?lang=en_us&edition=fundamental","pubTime":"2024-08-16 13:47","pubTimestamp":1723787245,"startTime":"0","endTime":"0","summary":"Huadong Medicine , through its unit Hangzhou Sino-US Huadong Pharmaceutical, has obtained an exclusive license for two of IMBiologics' autoimmune drugs, according to a Friday disclosure on the Shenzhen Stock Exchange.Huadong Medicine will pay the South Korean biotech company an initial payment of $6 million, a technology transfer milestone payment of $2 million, a development, registration and sales milestone payment of up to $307.5 million, and a tiered net sales royalty fee.The Chinese pharmaceutical company can sell the drugs, IMB-101 and IMB-102, in 37 Asian countries, including China. The company also received the rights to develop, register and produce the drugs.IMB-101, being developed to treat rheumatoid arthritis, is undergoing phase I clinical trials in the US. IMB-102, which is undergoing preclinical studies, has potential indications for moderate to severe atopic dermatitis and other autoimmune diseases, the company said.Price : 28.33, Change: +0.56, Percent Change: +2.02%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK0196","BK0132","000963","BK0183","BK0187","LU2328871848.SGD","BK0209","LU1969619763.USD","BK0175"],"gpt_icon":0},{"id":"2459252719","title":"Huadong Medicine Secures License For IMBiologics' Autoimmune Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2459252719","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459252719?lang=en_us&edition=fundamental","pubTime":"2024-08-16 13:47","pubTimestamp":1723787245,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK0188","BK0196","BK0132","000963","BK0183","BK0187","LU2328871848.SGD","BK0209","LU1969619763.USD","BK0175","SHE"],"gpt_icon":0},{"id":"2459723778","title":"Huadong Medicine's H1 Profit Jumps 18%, Operating Income Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459723778","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459723778?lang=en_us&edition=fundamental","pubTime":"2024-08-16 10:48","pubTimestamp":1723776485,"startTime":"0","endTime":"0","summary":"Huadong Medicine  posted first-half net profit attributable to shareholders of 1.70 billion yuan, or 0.9686 yuan per share, up 18% from 1.43 billion yuan, or 0.8190 yuan per share, in the same period the previous year.Operating income went up 3% year over year to 20.97 billion yuan from 20.39 billion yuan, according to a Friday filing with the Shenzhen bourse.The pharmaceutical company declared a cash dividend of 3.50 yuan per 10 shares.Huadong Medicine shares rose 2% in recent trade.Price : 28.33, Change: +0.56, Percent Change: +2.02%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["000963"],"gpt_icon":0},{"id":"2459423474","title":"Huadong Medicine  Says Unit Signs Exclusive License Agreement With South Korean Imbiologics Corp","url":"https://stock-news.laohu8.com/highlight/detail?id=2459423474","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459423474?lang=en_us&edition=fundamental","pubTime":"2024-08-15 19:53","pubTimestamp":1723722818,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240815:nL4N3K20Z7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0175","BK0187","BK0196","LU1969619763.USD","000963","BK0132","BK0183","BK0188","LU2328871848.SGD","BK0209"],"gpt_icon":0},{"id":"2457679917","title":"Huadong Medicine Buys Rights of ImmunoPharma Technology's Drug for Leukemia, Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2457679917","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457679917?lang=en_us&edition=fundamental","pubTime":"2024-08-05 12:11","pubTimestamp":1722831099,"startTime":"0","endTime":"0","summary":"Chinese pharmaceutical company Huadong Medicine's  unit, Huadong Medicine , agreed to acquire the exclusive commercialization rights of Beijing ImmunoPharma Technology's CD19-targeted autologous CAR-T candidate product IM19 chimeric antigen receptor T cell injection, according to the company's filing on the Shenzhen Stock Exchange.Huadong Medicine will receive an initial payment of 125 million yuan and registration and sales milestone payments of up to 950 million yuan.The drug is undergoing clinical trials as a treatment for relapsed or refractory diffuse large B cell lymphoma, acute B cell lymphoblastic leukemia and mantle cell lymphoma, the Sunday filing noted.Shares of the company rose more than 2% in recent trade.Price : 29.76, Change: +0.85, Percent Change: +2.94%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2328871848.SGD","BK0175","BK0187","BK0209","LU1969619763.USD","000963","BK0196","BK0183","BK0188","BK0132"],"gpt_icon":0},{"id":"2457427799","title":"Huadong Medicine Buys Rights of ImmunoPharma Technology's Drug for Leukemia, Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2457427799","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457427799?lang=en_us&edition=fundamental","pubTime":"2024-08-05 12:11","pubTimestamp":1722831099,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK0209","000963","LU1969619763.USD","BK0188","CAR","BK0175","BK0132","SHE","BK0196","BK4022","LU2328871848.SGD","BK4230","BK0183","BK0187"],"gpt_icon":0},{"id":"2453782644","title":"Huadong Medicine's Unit Gets Joint Rights to Quanxin Bio's Anti-Inflammatory Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2453782644","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2453782644?lang=en_us&edition=fundamental","pubTime":"2024-07-22 11:44","pubTimestamp":1721619877,"startTime":"0","endTime":"0","summary":"Huadong Medicine's  unit, Hangzhou Sino-US Huadong Pharmaceutical, obtained exclusive joint development and marking rights for the drug QX005N from Jiangsu Quanxin Biopharmaceutical, according to the company's filing on the Shenzhen Stock Exchange.Sino-US Huadong Pharmaceutical will be able to market the drug in authorized areas and Quanxin Bio will be responsible for the drug's production, supply, and quality control. Both parties will jointly carry out clinical research on the drug.Both parties bear 50% each of the registration fees, the Chinese pharmaceutical company said in its filing.The drug treats atopic dermatitis, nodular prurigo, chronic sinusitis with nasal polyps, chronic spontaneous urticaria, asthma, and chronic obstructive pulmonary disease.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0132","LU2328871848.SGD","000963","JYNT","BK0188","BK0209","LU1969619763.USD","BK0187","BK0175","BK4185","BK0183","BK0196"],"gpt_icon":0},{"id":"2453782505","title":"Huadong Medicine's Unit Gets Joint Rights to Quanxin Bio's Anti-Inflammatory Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2453782505","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2453782505?lang=en_us&edition=fundamental","pubTime":"2024-07-22 11:44","pubTimestamp":1721619877,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK0132","000963","BK0196","BK0188","LU2328871848.SGD","BK0187","BK0183","LU1969619763.USD","SHE","JYNT","BK4185","BK0209","BK0175"],"gpt_icon":0},{"id":"2451799574","title":"Sanyou Bio Collaborates on ADC Drug Development Entering Phase I Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2451799574","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2451799574?lang=en_us&edition=fundamental","pubTime":"2024-07-16 20:00","pubTimestamp":1721131219,"startTime":"0","endTime":"0","summary":"Sanyou Bio Collaborates on ADC Drug Development Entering Phase I Clinical Trials","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240716:nTUA68TK2Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ADC","BK0187","BK0196","BK0188","BK4231","BK0132","BK4080","BK0209","LU2328871848.SGD","BK0183","LU1969619763.USD","BK0175","000963"],"gpt_icon":0},{"id":"2451761682","title":"Huadong Medicine Buys Acute Ischemic Stroke Drug's Rights for 1.19 Billion Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=2451761682","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2451761682?lang=en_us&edition=fundamental","pubTime":"2024-07-15 16:59","pubTimestamp":1721033954,"startTime":"0","endTime":"0","summary":"Huadong Medicine , through unit Hangzhou Sino-US Huadong Pharmaceutical, bought the market rights for TTYP01 tablets from Suzhou Aozhong Biotechnology for 1.19 billion yuan, according to a Monday filing on the Shenzhen Stock Exchange.The fee includes development, regulatory and sales milestone payments. The company will pay a down payment of 100 million yuan.The Chinese pharmaceutical company will manufacture and sell the drug in China, Hong Kong, Macau and Taiwan.The drug for acute ischemic stroke already completed the phase III clinical studies and is expected to be submitted for marketing in the fourth quarter of the year.Price : 27.67, Change: -0.05, Percent Change: -0.18%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0183","LU2328871848.SGD","LU1969619763.USD","BK0132","BK0187","BK0175","BK0188","BK0209","BK0196","000963"],"gpt_icon":0},{"id":"2451616327","title":"Huadong Medicine Buys Acute Ischemic Stroke Drug's Rights for 1.19 Billion Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=2451616327","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2451616327?lang=en_us&edition=fundamental","pubTime":"2024-07-15 16:59","pubTimestamp":1721033954,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK0187","BK0188","SHE","BK0132","LU1969619763.USD","III","BK4134","BK0209","000963","BK0175","BK0196","BK0183","LU2328871848.SGD"],"gpt_icon":0},{"id":"2448823621","title":"Huadong Medicine's Unit Gets US FDA's Nod to Trial Tumor Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2448823621","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2448823621?lang=en_us&edition=fundamental","pubTime":"2024-07-02 16:26","pubTimestamp":1719908767,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK0187","BK0188","SHE","BK0132","LU1969619763.USD","BK0209","000963","BK0175","BK0196","BK0183","LU2328871848.SGD"],"gpt_icon":0},{"id":"2448182819","title":"Huadong Medicine's Unit Gets US FDA's Nod to Trial Tumor Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2448182819","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2448182819?lang=en_us&edition=fundamental","pubTime":"2024-07-02 16:26","pubTimestamp":1719908767,"startTime":"0","endTime":"0","summary":"Huadong Medicine's  unit, Hangzhou Sino-US Huadong Pharmaceutical, will conduct Phase I clinical trials on HDM2005 for injection in the US after receiving the approval of the country's Food and Drug Administration, according to the company's filing on the Shenzhen Stock Exchange.The drug will be tested as an antibody-drug conjugate targeting tumors, the Monday filing added.Shares of the company slipped more than 1% at the close.Price : 27.69, Change: -0.41, Percent Change: -1.46%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0196","000963","BK0209","LU2328871848.SGD","LU1969619763.USD","BK0188","BK0183","BK0187","BK0175","BK0132"],"gpt_icon":0},{"id":"2446639652","title":"BRIEF-Huadong Medicine Announces Positive Phase I Results For Innovative Oral Small Molecule GLP-1 Receptor Agonist HDM1002","url":"https://stock-news.laohu8.com/highlight/detail?id=2446639652","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2446639652?lang=en_us&edition=fundamental","pubTime":"2024-06-26 21:44","pubTimestamp":1719409448,"startTime":"0","endTime":"0","summary":"June 26  - Huadong Medicine Co Ltd   :   * HUADONG MEDICINE ANNOUNCES POSITIVE PHASE I RESULTS FOR INNOVATIVE ORAL SMALL MOLECULE GLP-1 RECEPTOR AGONIST HDM1002   * HUADONG MEDICINE CO LTD - HDM1002 SIGNIFICANTLY REDUCES POSTPRANDIAL BLOOD GLUCOSE LEVELS   * HUADONG MEDICINE - HDM1002 PHASE IB TRIAL SHOWS SIGNIFICANT WEIGHT LOSS IN 100MG OR HIGHER DOSE GROUPSource text for Eikon:    Further company coverage:    ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0196","BK0188","000963","LU2328871848.SGD","BK0183","LU1969619763.USD","BK0209","BK0175","BK0187","BK0132"],"gpt_icon":0},{"id":"2446989873","title":"Huadong Medicine Announces Positive Phase I Results for Innovative Oral Small Molecule Glp-1 Receptor Agonist Hdm1002","url":"https://stock-news.laohu8.com/highlight/detail?id=2446989873","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2446989873?lang=en_us&edition=fundamental","pubTime":"2024-06-26 20:57","pubTimestamp":1719406649,"startTime":"0","endTime":"0","summary":"Huadong Medicine Announces Positive Phase I Results for Innovative Oral Small Molecule Glp-1 Receptor Agonist Hdm1002","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240626:nTUA8DSRQR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0175","BK0187","BK0196","LU1969619763.USD","000963","BK0132","BK0183","BK0188","LU2328871848.SGD","BK0209"],"gpt_icon":0},{"id":"2446989853","title":"Huadong Medicine Co Ltd - Hdm1002 Significantly Reduces Postprandial Blood Glucose Levels","url":"https://stock-news.laohu8.com/highlight/detail?id=2446989853","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2446989853?lang=en_us&edition=fundamental","pubTime":"2024-06-26 20:57","pubTimestamp":1719406649,"startTime":"0","endTime":"0","summary":"Huadong Medicine Co Ltd - Hdm1002 Significantly Reduces Postprandial Blood Glucose Levels","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240626:nTUA8DSRQR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1969619763.USD","000963","BK0188","BK0132","BK0175","LU2328871848.SGD","BK0183","BK0187","BK0209","BK0196"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2000-01-27","address":"浙江省杭州市拱墅区中山北路439号4、7楼","stockEarnings":[{"period":"1week","weight":0.2461},{"period":"1month","weight":0.2022},{"period":"3month","weight":0.28},{"period":"6month","weight":0.1603},{"period":"1year","weight":-0.1454},{"period":"ytd","weight":-0.1293}],"companyName":"华东医药股份有限公司","boardCode":"AI0052","perCapita":"17811股","boardName":"零售业","registeredCapital":"175426万元","compareEarnings":[{"period":"1week","weight":0.2138},{"period":"1month","weight":0.1739},{"period":"3month","weight":0.1133},{"period":"6month","weight":0.0871},{"period":"1year","weight":0.0727},{"period":"ytd","weight":0.1215}],"survey":"　　华东医药股份有限公司主营业务是药品的研发、生产和销售。主要产品包括医药工业、医药商业、医美、工业微生物。公司医药工业深耕于专科,慢病用药及特殊用药领域的研发,生产和销售，并形成以慢性肾病,移植免疫,内分泌,消化系统等领域为主的核心产品管线。公司连续第十四年上榜财富中文网评选的《财富》中国500强，位列357位；入选米内网“2021年度中国医药工业百强”系列榜单，蝉联2021年度中国化药百强企业TOP10；荣膺全国工商联“2021年度中国医药制造业百强”“2021年度中国医药商业百强”，中国企业联合会“2022中国民营企业500强”“2022中国服务业企业500强”，荣获药智网“2022中国药品研发综合实力排行榜TOP100”“2022中国化药研发实力排行榜TOP100”。","serverTime":1728214223812,"listedPrice":5.76,"stockholders":"98302人(较上一季度增加4.76%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Huadong Medicine Co.,Ltd.(000963),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Huadong Medicine Co.,Ltd.(000963) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Huadong Medicine Co.,Ltd.,000963,Huadong Medicine Co.,Ltd.股票,Huadong Medicine Co.,Ltd.股票老虎,Huadong Medicine Co.,Ltd.股票老虎国际,Huadong Medicine Co.,Ltd.行情,Huadong Medicine Co.,Ltd.股票行情,Huadong Medicine Co.,Ltd.股价,Huadong Medicine Co.,Ltd.股市,Huadong Medicine Co.,Ltd.股票价格,Huadong Medicine Co.,Ltd.股票交易,Huadong Medicine Co.,Ltd.股票购买,Huadong Medicine Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Huadong Medicine Co.,Ltd.(000963),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Huadong Medicine Co.,Ltd.(000963) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction